AirDuo Digihaler FDA Approval History
Last updated by Judith Stewart, BPharm on Sep 17, 2020.
FDA Approved: Yes (First approved July 15, 2019)
Brand name: AirDuo Digihaler
Generic name: fluticasone propionate and salmeterol
Dosage form: Inhalation Powder
Company: Teva Pharmaceuticals USA, Inc.
Treatment for: Asthma
AirDuo Digihaler (fluticasone propionate and salmeterol) is a corticosteroid and a long-acting beta2-adrenergic agonist (LABA) combination therapy for the treatment of asthma in patients aged 12 years and older.
AirDuo Digihaler contains a built-in electronic module that records and stores information about inhaler events. AirDuo Digihaler may be used with, and transmits information to, a mobile App.
AirDuo Digihaler does not need to be connected to the app in order to use the medicine.
Development timeline for AirDuo Digihaler
|Jul 15, 2019||Approval FDA Approves AirDuo Digihaler (fluticasone propionate and salmeterol) Inhalation Powder for Asthma|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.